Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD and Carboplatin in Gynecologic Tumors
NCT00189410Phase 2Completed
- Sponsor
- AGO Study Group
- Start
- Jun 2003
- Primary completion
- Sep 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in ovarian cancer, uterine cancer, Cervical Cancer (CC) and 1 more, sponsored by AGO Study Group. Primary endpoints: Tolerance and Response Rate. Started Jun 2003; status: completed.
02
Drugs
doxorubicin
03
Conditions
ovarian canceruterine cancerCervical Cancer (CC)Malignant mixed Müllerian tumor (MMMT)
Beyond the preview
Go deeper on NCT00189410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189410.